OUR SCIENCE

AI APPROACHES POISED TO DISRUPT NEW AREAS OF DRUG DISCOVERY

lines v2

WHAT ARE GEMINI DIGITAL TWINS?

Gemini Digital Twins are computational representations of disease that capture genetic and molecular interactions that causally drive clinical and physiological outcomes.

lines v2

RAPID DISCOVERY OF NOVEL DRUG CANDIDATES IN SPECIFIC PATIENT POPULATIONS

PATIENT
DATA
arrow1
RIGHT
TARGET

Simulate genetic knockdowns in the Gemini Digital Twins to discover and cross validate novel drug targets that are causally linked to clinical endpoints

arrow2
RIGHT
DRUG

Genetically and biologically validate novel drug targets to add additional evidence to the novel targets through conducting a range of wet lab assays

arrow3
RIGHT
PATIENTS

Identify and advance molecular entities into development candidates and IND-enabling studies

arrow11

Continuously apply Gemini Digital Twins to inform translational medicine approach, identify specific patient populations, and optimize clinical trial designs

pill jar

Significantly increased probability of success

lines v2

We are disrupting the most critical areas of drug discovery and development in diseases of high unmet need with our best-in-class AI platform

segmentation

Deriving insights from Human datasets; by starting with human data, Aitia eliminates the need to use outdated model systems that are poor predictors of human biology

Union 2

Discovering targets at a speed and scale that is not possible through high-throughput experiments or other platforms; Aitia evaluates the impact of trillions of parameters on clinical outcomes in each of trillions of simulation experiments

Union 4

Identifying targets causally linked to clinical outcomes decades before anyone else; Aitia runs counter factual “in silico” experiments testing hypotheses across millions of patient-data derived Digital Twins

research 3

Starting with biomarkers and targets tied to specific patient populations and identifying responders vs non-responders early in development

lines v2

FIRST-IN-KIND PROGRAMS PRIORITIZING NEURODEGENERATIVE DISEASES

lines v2

AITIA’S PIPELINE OF DIFFERENTIATED, NOVEL PROGRAMS

NEUROLOGY
Huntington’s Disease
Huntington’s Disease
Alzheimer’s Disease
Alzheimer’s Disease
Parkinson’s Disease
ONCOLOGY
Pancreatic Cancer
Discovery
Pre-Clinical
Image 5@2x
lines v2

Ways to work with us